30岁以下患者生物瓣肺动脉瓣置换术后再干预率的多中心分析
基于8个中心1996至2015年间1278例30岁以下接受外科生物瓣肺动脉瓣置换(PVR)患者的回顾性数据,评估不同瓣膜类型的再干预时间及预测因素。平均PVR年龄19.3±12.8岁,中位随访3.9年,再干预率12.7%,多因肺动脉狭窄(68.8%),再干预多发生于儿童(85.2%)及较小瓣膜尺寸(P < .001)。控制年龄和瓣膜尺寸后,再干预的独立危险因素为未同期行三尖瓣手术(P = .02)和瓣膜类型(P < .001)。
要点
- 1、3、5、10年免于再干预率分别为99%、97%、92%、65%
- 再干预多因肺动脉狭窄(68.8%),且多发生于儿童(85.2%)
- 控制年龄与瓣膜尺寸后,瓣膜类型与未同期三尖瓣手术为独立危险因素
核心结论
- 在30岁以下患者的外科生物瓣PVR中,5年内8%患者接受再干预,再干预率独立于年龄和瓣膜尺寸而随瓣膜类型变化。
研究设计与样本
- 多中心回顾性研究,纳入8个中心1996至2015年间1278例30岁以下接受PVR的患者。
主要发现
- 平均PVR年龄19.3±12.8岁,719例(56.3%)≤18岁;法洛四联症626例(50.5%),165例(12.9%)有既往PVR。
- 中位随访3.9年(四分位距1.2, 6.4);再干预率12.7%,最常见原因为肺动脉狭窄(68.8%)。
- 再干预多发生于儿童(85.2%)及较小瓣膜尺寸(P < .001)。
- 1、3、5、10年免于再干预率分别为99%、97%、92%、65%。
- 控制年龄和瓣膜尺寸后,再干预独立危险因素为未同期行三尖瓣手术(P = .02)和瓣膜类型(P < .001)。
关键数值与推荐
- 再干预率12.7%,其中肺动脉狭窄占68.8%。
- 1、3、5、10年免于再干预率分别为99%、97%、92%、65%。
- 控制年龄和瓣膜尺寸后,未同期三尖瓣手术(P = .02)和瓣膜类型(P < .001)为再干预独立危险因素。
- 孤立性肺动脉反流手术指征与较低再干预风险相关(P < .001)。
临床怎么用
- 年轻患者选择生物瓣肺动脉瓣时应考虑瓣膜类型对再干预率的影响,Sorin与St Jude瓣膜再干预时间相似且退化更快。
- 同期三尖瓣手术可能与较低再干预风险相关,术前规划可予考虑。
局限性
- 回顾性多中心设计,中位随访仅3.9年,可能低估长期再干预率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the difference in time to and predictors of reintervention according to valve type in surgical bioprosthetic pulmonary valve replacement (PVR) in patients younger than 30 years of age from multiple centers. METHODS: Data were retrospectively collected for 1278 patients <30 years of age undergoing PVR at 8 centers between 1996 and 2015. RESULTS: Mean age at PVR was 19.3 ± 12.8 years, with 719 (56.3%) patients ≤18 years of age. Diagnosis was tetralogy of Fallot in 626 patients (50.5%) and 165 (12.9%) had previous PVR. Median follow-up was 3.9 years (interquartile range, 1.2, 6.4). Multiple valve types were used, most commonly CE PERIMOUNT, 488 (38.2%), CE Magna/Magna Ease, 361 (28.2%), and Sorin Mitroflow 322 (25.2). Reintervention occurred in 12.7% and was most commonly due to pulmonary stenosis (68.8%), with most reinterventions occurring in children (85.2%) and with smaller valve sizes (P < .001) Among adults aged 18 to 30 years, younger age was not a significant risk factor for reintervention. Surgical indication of isolated pulmonary regurgitation was associated with a lower risk of reintervention (P < .001). Overall, 1-, 3-, 5-, and 10-year freedom from reintervention rates were 99%, 97%, 92%, and 65%. The only independent risk factors for reintervention after controlling for age and valve size were lack of a concomitant tricuspid valve procedure (P = .02) and valve type (P < .001); Sorin and St Jude valves were associated with similar time to reintervention, and deteriorated more rapidly than other valve types. CONCLUSIONS: In this large multicenter study, 8% of patients have undergone reintervention by 5 years. Importantly, independent of age and valve size, reintervention rates vary by valve type.
引用
- Baird CW, Chávez M, Sleeper LA, et al. Reintervention rates after bioprosthetic pulmonary valve replacement in patients younger than 30 years of age: A multicenter analysis. J Thorac Cardiovasc Surg. 2020. PMID: 33069421. doi:10.1016/j.jtcvs.2020.06.157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。